Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Ibrutinib has demonstrated high response rates in B-cell lymphomas but a lot of ibrutinib-treated patients relapse with resistance. This study unified TME-mediatedde novoand acquired drug resistance through B-cell receptor signalling and PI3K-AKT-mTOR axis and provides a combination therapeutic stra...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms14920 |